Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
|Articles|March 18, 2021
Deloitte Releases 12th Annual Life Sciences Industry Accounting Guide
Report provides comprehensive look at financial and accounting issues faced by life sciences industry.
Advertisement
On Mar. 16 Deloitte released its 12th annual Life Sciences Industry Accounting Guide. The report provides a comprehensive look at some of the complex issues that finance and accounting professionals in the life sciences industry face including R&D costs, acquisitions and divestitures, consolidation, contingencies, revenue recognition, income taxes, financial instruments, and financial statement presentation and disclosure.
Some of the main themes from this year’s edition include:
- COVID-19-Related Accounting and Financial Reporting Considerations for Life Sciences Entities
- IPOs and SPACs
- Revenue Recognition
- Structured Trade Payable Arrangement
For additional information and the full report, click
Advertisement
Related to this article
Orbis Medicines strikes a partnership with Novo, Dualitas Therapeutics enters collaboration with Roche, and Aethlon Medical has agreed to merge with North Immunology.
Sling Therapeutics closes a $123 million Series C to advance linsitinib, while Circle Pharma raises an oversubscribed $92.5 million Series E to move CID-165, into clinical development for ER-positive breast cancer.
A new benchmarking survey of 33 biotech and medtech leaders reveals a leadership community operating in crisis mode — and what that means for how the industry needs to rethink peer support, advisory and the isolation built intothe CEO role itself.
Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan argues health care needs an orchestration layer rather than more point solutions, and Nacho Quinones and Aisling O'Loughlin make the case for synthetic advisory boards in biopharma decision-making.
Novartis shareholders share deepened trust issues around the company's dealmaking strategy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
3
Why Executive MFN Deals Aren't Enough: Q&A with Joe Cunningham
4
The Battle to Own the GLP-1 Patient Journey
5